论文部分内容阅读
[目的]评价调强放射治疗(IMRT)治疗鼻咽癌近期疗效和急性反应。[方法]50例初治鼻咽癌患者进行全程IMRT治疗(IMRT组),同时50例行常规放疗(CRT组)。所有的T3～4,N2～3病例均接受(顺铂或奈达铂每天30mg/m2)同步化疗,分别于d1～3,d22～24,d43～45进行。肿瘤疗效参照WHO标准,急性期反应评价参照RTOG标准。[结果]所有病例均完成放疗,近期疗效IMRT组CR率为98.0%,高于CRT组的86.0%,但差异无统计学意义(P=0.0650)。IMRT组口干反应较CRT组轻(P=0.000),两组骨髓抑制无显著性差异(P=0.308)。[结论]IMRT可以一定程度提高鼻咽癌的局部区域控制率且降低副反应率。
[Objective] To evaluate the short-term efficacy and acute response of IMRT in the treatment of nasopharyngeal carcinoma. [Method] Fifty patients with newly diagnosed nasopharyngeal carcinoma underwent IMRT (IMRT group) while 50 patients received conventional radiotherapy (CRT group). All T3 ~ 4 and N2 ~ 3 patients underwent synchronous chemotherapy (30mg / m2 of cisplatin or nedaplatin daily), and were performed on d1 ~ 3, d22 ~ 24 and d43 ~ 45 respectively. Tumor efficacy with reference to WHO standards, acute phase response evaluation reference RTOG standard. [Results] The radiotherapy was completed in all cases. The CR rate in the short-term IMRT group was 98.0%, which was higher than that in CRT group (86.0%), but the difference was not statistically significant (P = 0.0650). The IMRT group had less dry mouth reaction than CRT group (P = 0.000). There was no significant difference in bone marrow suppression between the two groups (P = 0.308). [Conclusion] IMRT can improve the local control rate of nasopharyngeal carcinoma and reduce the incidence of side effects.